News

Wilmington, MA March 26, 2018—Micro Medical Solutions is pleased to announce an organizational change that includes the promotions of three key members of the company’s executive team. Greg Mathison will now take over the role of Vice President of Regulatory Affairs, and Tim Robinson steps into the position of Vice President, Research and Development. Additionally, Jared Dyer is now Vice President, Quality Assurance.

These promotions reflect the increasing momentum behind Micro Medical Solutions as it grows closer to fully commercializing the Micro Vascular Integrated Platform (mVIP) in the European and Latin American markets.

“I’m excited to move forward with this strong and talented leadership team,” says Gregory Sullivan, CEO of Micro Medical Solutions. “This is one of the key key elements in positioning us for a successful 2018 as we continue to work towards innovative solutions for the below-the-knee critical limb ischemia market,” he says.

About CLI

Peripheral artery disease (PAD) and critical limb ischemia (CLI) affected 215 million people worldwide in 2015, predicted to be 230 million by 2020.1 CLI currently afflicts 2.8 to 3.5 million of those with PAD and is projected to rise to 4.5 to 5.6 million.2 Rates of amputations in the general population with PAD are declining, but amputations in CLI continue to escalate. It has been estimated that 25% of CLI patients will undergo major amputation. Prognosis with respect to limb preservation in CLI patients is poor, particularly in no-option CLI patients, where six-month major amputation rates have been reported to be as high as 50%.3 If something doesn’t change, the number of amputations due to CLI could exceed one million by 2030.